Inegy

Simvastatin, the active ingredient in Inegy, is a HMG‑CoA reductase inhibitor presented as a fixed‑dose combination tablet for oral use. It works together with ezetimibe to lower low‑density lipoprotein cholesterol and total cholesterol, addressing hypercholesterolemia, mixed dyslipidemia, and primary hyperlipidemia in adult patients.

GNH USA supplies Inegy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory support for global distribution. The company adheres to stringent quality standards and offers comprehensive logistics solutions to meet the needs of healthcare providers across multiple regions.

Inegy combines simvastatin and ezetimibe to lower cholesterol by targeting both synthesis and absorption pathways, and is indicated for the following lipid disorders:

Hypercholesterolemia: reduces low‑density lipoprotein cholesterol and total cholesterol, helping achieve target lipid levels in adults with elevated cholesterol. Mixed dyslipidemia: improves the overall lipid profile, including reductions in LDL‑C, total cholesterol, and triglycerides, for patients with combined lipid abnormalities. Primary hyperlipidemia: lowers elevated cholesterol concentrations in patients with familial or genetic lipid disorders, supporting long‑term cardiovascular risk management.

Inegy may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Muscle aches or weakness - Elevated liver enzymes (ALT, AST) - Gastrointestinal discomfort such as nausea or diarrhea - Headache - Dizziness - Fatigue

Serious or Rare Side Effects: - Rhabdomyolysis leading to renal impairment - Severe hepatic injury or hepatitis - Acute allergic reactions including rash and angioedema - Myopathy with marked CK elevation - Pancreatitis

Before initiating therapy with Inegy, consider the following safety measures:

Liver function monitoring: obtain baseline and periodic ALT/AST levels. Muscle symptom vigilance: advise patients to report unexplained muscle pain or weakness. Drug interaction awareness: avoid concomitant use of strong CYP3A4 inhibitors. Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. Renal impairment: adjust therapy based on renal function and monitor for accumulation. Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Inegy can interact with several medications; careful assessment is required.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin) - Gemfibrozil - Cyclosporine - High‑dose niacin - Certain HIV protease inhibitors

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium - Warfarin (may increase INR) - Digoxin (potential increased serum levels) - Beta‑blockers (enhanced lipid‑lowering effect) - Fibrates (monitor for muscle toxicity)